公开(公告)号：US08980903B2

公开(公告)日：2015-03-17

申请号：US14453842

申请日：2014-08-07

Applicant: Amgen Inc.

Inventor： Richard V. Connors ,  Kang Dai ,  John Eksterowicz ,  Pingchen Fan ,  Benjamin Fisher ,  Jiasheng Fu ,  Kexue Li ,  Zhihong Li ,  Lawrence R. McGee ,  Rajiv Sharma ,  Xiaodong Wang ,  Dustin L. McMinn ,  Jeffrey T. Mihalic ,  Jeffrey Deignan

IPC: C07D498/04 ,  C07D491/147 ,  C07D471/14 ,  C07D471/04 ,  C07D487/14 ,  C07D491/107 ,  C07D498/10

CPC classification number: C07D471/14 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/14 ,  C07D491/107 ,  C07D491/147 ,  C07D498/04 ,  C07D498/10 ,  C07D513/14

Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

Abstract translation: 提供了可用于治疗CDK4介导的疾病如癌症的化合物，药物组合物和方法。 本发明化合物是吡啶，吡嗪酰亚胺和三嗪衍生物。

公开(公告)号：US20140011796A1

公开(公告)日：2014-01-09

申请号：US14025688

申请日：2013-09-12

Applicant: AMGEN INC.

Inventor： Michael David BARTBERGER ,  Ana Gonzalez Buenrostro ,  Hilary Plake Beck ,  Xiaoqi Chen ,  Richard Victor Connors ,  Jeffrey Deignan ,  Jason Duquette ,  John Eksterwicz ,  Benjamin Fisher ,  Brian Matthew Fox ,  Jiasheng Fu ,  Zice Fu ,  Felix Gonzalez Lopez De Turiso ,  Michael William Gribble ,  Dann James Gustin ,  Julie Anne Heath ,  Xin Huang ,  Xianyun Jiao ,  Michael Johnson ,  Frank Kayser ,  David John Kopecky ,  Sujen Lai ,  Yihong Li ,  Zhihong Li ,  Jiwen Liu ,  Jonathan Dante Low ,  Brian Stuart Lucas ,  Zhihua Ma ,  Lawrence R. McGee ,  Joel McIntosh ,  Dustin McMinn ,  Julio Cesar Medina ,  Jeffrey Thomas Mihalic ,  Steven Howard Olson ,  Yosup Rew ,  Philip Marley Roveto ,  Daqing Sun ,  Xiaodong Wang ,  Yingcai Wang ,  Xuelei Yan ,  Ming Yu ,  Jiang Zhu

IPC: C07D211/76 ,  C07D417/12 ,  C07D413/06 ,  C07D471/10 ,  C07D409/04 ,  C07D401/04 ,  C07D279/02 ,  C07D491/08 ,  C07D498/08 ,  C07D417/14 ,  C07D491/153 ,  C07D417/06 ,  C07D401/06 ,  C07D405/04

CPC classification number: C07D211/76 ,  C07D221/20 ,  C07D279/02 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D407/04 ,  C07D407/06 ,  C07D409/04 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  C07D491/08 ,  C07D491/153 ,  C07D498/08 ,  C07D498/14 ,  C07D498/20

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.